Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?
Current Prediction
Why This Question Matters
Any unplanned DSMB safety communication during the 2026 Phase 3 ramp would be a critical tail-risk signal for Black Swan Beacon's 'Safety Signal at Phase 3 Scale' compound scenario (10-15% probability, EXISTENTIAL severity). Serotonergic psychedelics carry theoretical 5-HT2B-linked cardiovascular risk that Phase 2b (n=196) is too small to detect. A YES resolution would propagate through REGULATORY_EXPOSURE and TAIL_RISK_SEVERITY; a NO resolution confirms safety profile scales. Low base rate but asymmetric impact.
Prediction Distribution
Individual Predictions(9 runs)
Three-factor decomposition: (1) P(Phase 3 enrollment starts by Q3 2026) ~65%, (2) P(first DSMB review occurs within 3-6 months of FPD i.e. before 2026-12-31) ~40%, (3) P(unplanned communication at that review) ~8% base rate. Joint conditional probability of ATAI-specific unplanned DSMB event by 2026-12-31: 0.65 x 0.40 x 0.08 = 0.021. Add Category Backlash path (~7-12% probability of competitor-driven FDA class communication): approximately 5-8% additional probability. Net approximately 0.08 — dominated by category effect more than direct safety signal.
The Phase 2b safety profile was favorable (n=196, no serious drug-related AEs, patients discharge-ready in 2 hours). Breakthrough Therapy status enables FDA to intervene via protocol amendments BEFORE DSMB escalation — this lowers formal DSMB action probability meaningfully. Direct safety event probability 3-5%; category backlash probability 5-8%; some correlation but approximate union 0.10. Tail scenario includes 5-HT2B cardiovascular signal — theoretical but low near-term probability.
Slightly elevated. The post-Lykos FDA scrutiny environment may lower the threshold for proactive DSMB communication — what would have been handled informally pre-2024 may now be formalized. Add 3-4% to base estimate for this elevated regulatory posture. Also consider that ATAI's dosing protocol (monitored clinical settings, 2-hour observation) is designed to surface AEs quickly, which increases the probability that any observed signal escalates to DSMB attention. Net 0.12.
Base rate for unplanned DSMB communication in Phase 3 psychiatric drug trial within first 6-8 months of enrollment: 3-6%. Category backlash path adds 4-6%. If Phase 3 FPD slips, the window compresses (mechanically reduces probability). Weighted net 0.09. Strict definition of 'unplanned' filters out routine DSMB outputs.
Conservative. Phase 2b clean safety + Breakthrough designation + monitored clinical setting + short 2026 observation window all point to low probability. Most meaningful DSMB interactions will happen 2027+. The 'unplanned' strict definition is a significant filter — many DSMB reviews are scheduled and produce routine outputs that do not qualify. Net 0.07.
Balanced. Direct signal 4-5%, category effect 5-6%, weak correlation implies approximate union 0.09-0.11. Post-Lykos environment + serotonergic class theoretical risks + 700-1000 patient Phase 3 scale all support ~0.10. Phase 2b positive safety is the strongest counterweight but has limited power for rare events.
Base rate 3-6% for unplanned DSMB in psychiatric Phase 3 first 6-8 months. Category path 4-6%. Union 0.08.
Serotonergic psychedelic class + post-Lykos scrutiny + 700-1000 patient scale elevate above pure base rate. Still dominated by low base rate for any single-window event. 0.09.
Base rate anchor. Phase 2b safety clean + Breakthrough + 2026 window mostly pre-meaningful-data = low probability. 0.08.
Resolution Criteria
Resolves YES if by 2026-12-31 ATAI publicly discloses (via 8-K, press release, earnings call, or ClinicalTrials.gov update) any unplanned DSMB communication for BPL-003 Phase 3 trials — including but not limited to: enrollment pause, protocol amendment triggered by safety review, serious adverse event notification, activation of a stopping rule, or DSMB recommendation to FDA. Resolves NO if no such disclosure occurs by 2026-12-31. Planned/scheduled interim DSMB meetings without safety-driven recommendations do NOT trigger YES.
Resolution Source
ATAI 8-K filings, press releases, quarterly earnings calls, ClinicalTrials.gov updates, FDA safety communications
Source Trigger
DSMB interim safety communications — any unplanned DSMB disclosure
Full multi-lens equity analysis